Kadmon (KDMN) Trading Down 5.4%

Kadmon Holdings Inc (NYSE:KDMN)’s share price traded down 5.4% during mid-day trading on Monday . The stock traded as low as $4.09 and last traded at $4.24. 528,491 shares were traded during trading, a decline of 52% from the average session volume of 1,108,311 shares. The stock had previously closed at $4.48.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Kadmon from a “strong sell” rating to a “hold” rating in a report on Saturday, March 10th. Piper Jaffray Companies reiterated a “positive” rating and issued a $9.00 target price (up previously from $7.00) on shares of Kadmon in a research report on Tuesday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research report on Friday, March 9th. Finally, Jefferies Group upped their target price on Kadmon to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $10.21.

How to Become a New Pot Stock Millionaire

The company has a market capitalization of $352.32, a PE ratio of -2.85 and a beta of 5.59.

Kadmon (NYSE:KDMN) last issued its earnings results on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.12. The firm had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $3.07 million. Kadmon’s quarterly revenue was down 65.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) EPS. research analysts anticipate that Kadmon Holdings Inc will post -1.11 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of KDMN. Goldman Sachs Group Inc. purchased a new stake in Kadmon in the second quarter valued at approximately $114,000. Bank of New York Mellon Corp purchased a new stake in Kadmon in the 3rd quarter worth approximately $119,000. Old West Investment Management LLC purchased a new stake in Kadmon in the 3rd quarter worth approximately $169,000. Wells Fargo & Company MN boosted its position in Kadmon by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares in the last quarter. Finally, BlueCrest Capital Management Ltd purchased a new stake in Kadmon in the 4th quarter worth approximately $241,000. Hedge funds and other institutional investors own 61.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3278973/kadmon-kdmn-trading-down-5-4.html.

About Kadmon

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Contrasting Roku  & Its Peers
Contrasting Roku & Its Peers
Head-To-Head Analysis: FuelCell Energy  and Its Peers
Head-To-Head Analysis: FuelCell Energy and Its Peers
Reviewing Wolverine World Wide  and Steve Madden
Reviewing Wolverine World Wide and Steve Madden
JavaScript Token Hits Market Cap of $64,282.00
JavaScript Token Hits Market Cap of $64,282.00
Patientory  Price Reaches $0.21 on Top Exchanges
Patientory Price Reaches $0.21 on Top Exchanges
eUSD 1-Day Volume Hits $0.00
eUSD 1-Day Volume Hits $0.00


© 2006-2018 Ticker Report. Google+.